Alzheon CEO Martin Tolar interview with Generation Bold, a Radio Public podcast with host Adriane Berg, one of the most credentialed and recognized broadcasters and speakers on aging in the nation and internationally
Alzheon CEO Martin Tolar interviews with Generation Bold Podcast host Adriane Berg, discussing a new era in AD drug development & recent breakthroughs for Alzheon and Alzheimer’s alike.
“In their 40 or 50’s people start having changes in the brain and then only after there is very substantial damage to the brain, you start having clinical symptoms. Our goal, ultimately, is to prevent the onset of these clinical symptoms.” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon.
Use the outline below to jump to the answers you want to hear within this video interview:
How would you describe the Life Sciences career path? [2:21]
With your breakthrough, will this one medicine deal only with the Alzheimer’s issues or will it also deal with some of the others and what are you doing in that field? [5:27]
Demystifying “It’s not gonna happen to me” [6:54]
Why did you call your study APOLLOE4? [9:52]
Paint us a word picture, let us say everything goes exactly as you wish. And it’s approved, it proves extremely successful without any ambiguity as to the benefits to the patient, somebody is diagnosed with Early Onset Alzheimer’s. What will happen, what will they take, what do you think the effect will be for their future? [11:02]
Can you explain that (vasogenic edema) so that people have an awareness of the potential issues as well as the benefits? [13:58]
Explain that (biomarkers) in the context of wanting to have evidence based results for the benefits of the drugs that you’re looking at. [18:40]
How do you pick Biomarker vendors? [22:20]
If you could make a regulatory change, what would it be? [25:58]
What are your next steps? What do you think Alzheon is going to be focusing on? Will it always be Alzheimer’s? Will it be aging itself? [31:58]